COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients

COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clini...

Full description

Saved in:
Bibliographic Details
Published in:J Med Virol
Main Authors: Chakraborty, Chiranjib, Sharma, Ashish Ranjan, Bhattacharya, Manojit, Sharma, Garima, Lee, Sang‐Soo, Agoramoorthy, Govindasamy
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7283789/
https://ncbi.nlm.nih.gov/pubmed/32462717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.26078
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items